Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stuart A Nicklin

Showing results (51-60 of 79) with videos related to

Pageof 8
Sort By:
FEBS Letters|June 2, 2009
Use of in vivo phage display to engineer novel adenoviruses for targeted delivery to the cardiac vasculatureCampbell G Nicol, Laura Denby, Oscar Lopez-Franco, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|January 3, 2006
Vascular bed-targeted in vivo gene delivery using tropism-modified adeno-associated virusesLorraine M Work, Hildegard Büning, Ela Hunt, et al.
British Journal of Pharmacology|June 16, 2021
Preclinical models of myocardial infarction: from mechanism to translationTamara P Martin, Eilidh A MacDonald, Ali Ali Mohamed Elbassioni, et al.
Journal of Virology|January 26, 2007
Influence of coagulation factor zymogens on the infectivity of adenoviruses pseudotyped with fibers from subgroup DAlan L Parker, John H McVey, Jessica H Doctor, et al.
Plos Pathogens|February 7, 2015
Manipulating adenovirus hexon hypervariable loops dictates immune neutralisation and coagulation factor X-dependent cell interaction in vitro and in vivoJiangtao Ma, Margaret R Duffy, Lin Deng, et al.
ESC Heart Failure|March 11, 2026
Optimised murine HFpEF models for translational pre-clinical studiesBailey McIntosh, Ali Ali Mohamed Elbassioni, Anmar Raheem, et al.
The Journal of Pharmacology and Experimental Therapeutics|September 13, 2012
Antagonists of GPR35 display high species ortholog selectivity and varying modes of actionLaura Jenkins, Nicholas Harries, Jennifer E Lappin, et al.
Cardiovascular Research|January 11, 2019
What matters in Cardiovascular Research? Scientific discovery driving clinical deliveryTomasz J Guzik, Charalambos Antoniades, Andrew H Baker, et al.
Molecular Pharmacology|October 12, 2013
The antiallergic mast cell stabilizers lodoxamide and bufrolin as the first high and equipotent agonists of human and rat GPR35Amanda E MacKenzie, Gianluigi Caltabiano, Toby C Kent, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|August 30, 2012
Ad5:Ad48 hexon hypervariable region substitutions lead to toxicity and increased inflammatory responses following intravenous deliveryLynda Coughlan, Angela C Bradshaw, Alan L Parker, et al.
Pageof 8

Showing results (51-60 of 79) with videos related to

Sort By:
Pageof 8
FEBS Letters|June 2, 2009
Use of in vivo phage display to engineer novel adenoviruses for targeted delivery to the cardiac vasculatureCampbell G Nicol, Laura Denby, Oscar Lopez-Franco, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|January 3, 2006
Vascular bed-targeted in vivo gene delivery using tropism-modified adeno-associated virusesLorraine M Work, Hildegard Büning, Ela Hunt, et al.
British Journal of Pharmacology|June 16, 2021
Preclinical models of myocardial infarction: from mechanism to translationTamara P Martin, Eilidh A MacDonald, Ali Ali Mohamed Elbassioni, et al.
Journal of Virology|January 26, 2007
Influence of coagulation factor zymogens on the infectivity of adenoviruses pseudotyped with fibers from subgroup DAlan L Parker, John H McVey, Jessica H Doctor, et al.
Plos Pathogens|February 7, 2015
Manipulating adenovirus hexon hypervariable loops dictates immune neutralisation and coagulation factor X-dependent cell interaction in vitro and in vivoJiangtao Ma, Margaret R Duffy, Lin Deng, et al.
ESC Heart Failure|March 11, 2026
Optimised murine HFpEF models for translational pre-clinical studiesBailey McIntosh, Ali Ali Mohamed Elbassioni, Anmar Raheem, et al.
The Journal of Pharmacology and Experimental Therapeutics|September 13, 2012
Antagonists of GPR35 display high species ortholog selectivity and varying modes of actionLaura Jenkins, Nicholas Harries, Jennifer E Lappin, et al.
Cardiovascular Research|January 11, 2019
What matters in Cardiovascular Research? Scientific discovery driving clinical deliveryTomasz J Guzik, Charalambos Antoniades, Andrew H Baker, et al.
Molecular Pharmacology|October 12, 2013
The antiallergic mast cell stabilizers lodoxamide and bufrolin as the first high and equipotent agonists of human and rat GPR35Amanda E MacKenzie, Gianluigi Caltabiano, Toby C Kent, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|August 30, 2012
Ad5:Ad48 hexon hypervariable region substitutions lead to toxicity and increased inflammatory responses following intravenous deliveryLynda Coughlan, Angela C Bradshaw, Alan L Parker, et al.
Pageof 8